Incyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte today announced eight winners of the 2026 MPN Heroes® annual recognition program. The program, now in its 14th year, pays tribute to individuals whose contributions to patient care, research and advocacy make a meaningful difference for people affected by myeloproliferative neoplasms (MPNs). The 2026 Heroes join a distinguished group of over 100 past honorees whose remarkable contributions have spurred progress and enriched the lives of people throughou.

Business Wire • Oct 13, 2026

Incyte to Report Third Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--3Q26 Earnings Announcement.

Business Wire • Oct 8, 2026

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA's rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1

GlobeNewsWire • Oct 6, 2026

INCY or TECH: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Techne (TECH). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Sep 30, 2026

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secretary.

PRNewsWire • Sep 28, 2026

MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy

Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.

Zacks Investment Research • Sep 28, 2026

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva.

Business Wire • Sep 25, 2026

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio.

Business Wire • Sep 22, 2026

Is First Trust Large Cap Growth AlphaDEX ETF (FTC) a Strong ETF Right Now?

The First Trust Large Cap Growth AlphaDEX ETF (FTC) was launched on 05/08/2007, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - Large Cap Growth category of the market.

Zacks Investment Research • Sep 22, 2026

Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029.

MarketBeat • Sep 20, 2026